Integer Holdings Corporation — Q2 2023 Form 10-Q Summary
Business context and reporting period
Integer is a medical device outsource manufacturer serving cardiac rhythm management, neuromodulation, cardiovascular, orthopedics, vascular, advanced surgical and portable medical markets. It also develops batteries for niche energy, military and environmental applications. The Company reports Medical and Non-Medical segments. The quarter ended June 30, 2023 comprised 91 days; the comparable quarter ended July 1, 2022 also comprised 91 days.
Financial performance and key metrics
| Metric | Q2 2023 | Q2 2022 | Change |
|---|---|---|---|
| Sales | $400.0 million | $350.1 million | 14.3% increase |
| Gross profit | $105.8 million | $92.9 million | 13.9% increase |
| Gross margin | 26.4% | 26.5% | 10 basis-point decrease |
| Operating income | $41.6 million | $32.7 million | 27.1% increase |
| Operating margin | 10.4% | 9.3% | 110 basis-point increase |
| Net income | $24.0 million | $20.8 million | 15.0% increase |
| Diluted EPS | $0.71 | $0.62 | 14.5% increase |
| Effective tax rate | 19.8% | 14.7% | Increase |
| Interest expense | $11.5 million | $7.8 million | 47.4% increase |
For the first six months, sales were $778.8 million, up 17.8%; gross profit was $202.5 million, up 16.1%; gross margin was 26.0% versus 26.4%; operating income was $75.7 million, up 37.2%; net income was $37.0 million, up 15.0%; and diluted EPS was $1.10 versus $0.97. Six-month operating margin improved to 9.7% from 8.4%, while net margin was 4.8% versus 4.9%.
- Medical sales increased 14.5% in Q2 and 17.4% year to date. Cardio & Vascular sales rose 15.4% in Q2, Cardiac Rhythm Management & Neuromodulation rose 12.8%, and Advanced Surgical, Orthopedics & Portable Medical rose 16.8%.
- Non-Medical sales increased 6.7% in Q2 and 33.0% year to date, driven primarily by military and environmental demand.
- Operating expense growth was limited to 6.7% in Q2 and 6.3% year to date, supported by lower restructuring and other charges. SG&A and research, development and engineering expenses increased primarily from labor, amortization and technology-related costs.
Cash flow, liquidity and debt
| Metric | Six months ended June 30, 2023 | Six months ended July 1, 2022 |
|---|---|---|
| Cash provided by operating activities | $62.3 million | $37.0 million |
| Capital expenditures | $57.4 million | $22.6 million |
| Cash used in investing activities | $57.4 million | $148.7 million |
| Cash provided by financing activities | $7.6 million | $115.6 million |
| Ending cash and equivalents | $38.6 million | $15.6 million |
Cash increased by $14.3 million from December 31, 2022. Working capital was $416.1 million and the current ratio was 3.08 at June 30, 2023. A new receivables factoring arrangement generated approximately $23 million of incremental operating cash flow during the first six months; $50.3 million of receivables were sold without recourse and factoring fees were $0.4 million.
Debt, net of discounts and issuance costs, was $985.4 million at June 30, 2023, compared with $925.3 million at December 31, 2022. The Company issued $500 million of 2.125% convertible senior notes due 2028, generating approximately $485 million of net proceeds. Proceeds were used primarily to repay the $335.6 million Term Loan B, repay $113.9 million of revolving debt and fund related fees and capped calls. The revolving facility had $387.9 million of available capacity after borrowings and letters of credit. Approximately 50% of principal debt was fixed-rate or effectively fixed-rate at quarter-end, compared with 11% at year-end 2022.
The Company was in compliance with its debt covenants. The Total Net Leverage Ratio was approximately 2.9:1.0 versus a maximum of 5.50:1.0, stepping down to 5.00:1.0 beginning in the third quarter of 2023. The interest coverage ratio was approximately 7.9:1.0 versus a minimum of 2.50:1.0. Management stated that available cash, operating cash flow and revolver capacity are expected to be sufficient for working capital, debt service and capital expenditures for the next twelve months.
Material changes versus the prior comparable period
- Revenue growth reflected strong Medical demand, improved supply-chain and labor conditions, product ramps, and contributions from the Oscor and Aran acquisitions.
- Gross margin declined modestly because of labor and supply-chain costs, despite higher production volume.
- Operating margin improved due to revenue leverage, lower restructuring and acquisition-related charges, and SG&A deleveraging.
- Interest expense more than doubled year to date because of higher rates, higher average debt and approximately $4.4 million of debt extinguishment-related losses.
- Cash flow from operations improved by $25.3 million, partly because factoring accelerated collections. Capital spending increased substantially to support capacity and growth.
- The Company replaced a significant portion of floating-rate debt with fixed-rate convertible notes, reducing exposure to future rate increases but increasing total reported debt.
Guidance, outlook, commentary and risks
The filing does not provide a clear numerical revenue, earnings or capital-expenditure guidance range. Management cited continued demand, improving supply-chain conditions and manufacturing-capacity expansion as favorable factors, while noting that labor and supply constraints continue to pressure costs.
- Key risks include customer concentration, pricing pressure, reliance on third-party suppliers, manufacturing interruptions, labor availability, product quality or recall issues, cybersecurity, competition, acquisition integration and the ability to develop new products.
- Financial risks include substantial indebtedness, floating-rate exposure, covenant compliance, access to capital markets, foreign exchange volatility, international tax complexity and potential impairment of goodwill or intangible assets.
- Macroeconomic uncertainty includes inflation, rising interest rates, supply-chain disruption, currency volatility and the continuing effects of the Russia-Ukraine conflict.
- The Company reported no new material legal proceedings, no material changes to previously disclosed risk factors and no material changes in internal control over financial reporting.
- Restructuring and other charges were $1.5 million in Q2 and $3.0 million year to date, down from $3.5 million and $6.9 million, respectively, in the comparable periods.
- Malaysia’s tax holiday expired in April 2023, creating a potential source of future effective tax-rate pressure. Unrecognized tax benefits were approximately $8.0 million, of which approximately $1.9 million may be reduced within twelve months.
Investor verification points
- Verify whether Medical demand and supply-chain improvements persist and whether the modest gross-margin decline reverses.
- Monitor interest expense, floating-rate debt exposure and compliance with the leverage covenant step-down beginning in Q3 2023.
- Assess the sustainability of operating cash flow after excluding the benefit from receivables factoring.
- Track capital spending, manufacturing-capacity expansion and execution of restructuring and operational-efficiency programs.
- Evaluate potential dilution or cash obligations from the $500 million convertible notes, including the approximately 5.7 million shares initially underlying the notes.
- Monitor customer concentration, supplier constraints, regulatory and product-liability exposure, foreign exchange and international tax developments.